Regorafenib for advanced liver cancer after immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether regorafenib, a targeted cancer drug, can help patients with advanced liver cancer whose disease progressed after or couldn't tolerate first-line immunotherapy. The goal is to see if this drug can slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with hepatocellular carcinoma (liver cancer) confirmed by biopsy or imaging
- Cancer progressed or became intolerable during first-line immunotherapy (atezolizumab + bevacizumab, durvalumab + tremelimumab, or nivolumab + ipilimumab)
- At least one measurable tumor visible on imaging
- Liver function and blood counts meet specific thresholds (hemoglobin ≥8.5, platelets ≥60,000, bilirubin <3.5, albumin ≥2.5)
- No severe heart disease, gastrointestinal bleeding risk, or other major organ problems in the past 3–6 months
- Willing to use effective birth control for 6 months after last study dose (if able to have children)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether regorafenib, a targeted cancer drug, can help patients with advanced liver cancer (HCC) whose disease got worse or stopped tolerating lenvatinib, an earlier treatment. The goal is to see if switching to regorafenib can slow or shrink the cancer.
This study tests two targeted therapy drugs, lenvatinib or regorafenib, for people with advanced liver cancer that got worse after first treatment with immunotherapy. It aims to see if these drugs can help when immunotherapy stops working.
This trial tests whether adding trastuzumab to the standard drug regorafenib works better than regorafenib alone for people with advanced liver cancer that has grown after initial treatment. It is for those who have already received a type of immunotherapy combined with a targeted drug (like atezolizumab + bevacizumab).
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (regorafenib) for people with advanced hepatocellular carcinoma (liver cancer) that has gotten worse after or during first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
This study is for people with advanced liver cancer whose previous immunotherapy (such as Keytruda or Tecentriq) is no longer working. It tests a new combination: chemotherapy infused directly into the liver, plus an immunotherapy drug and a targeted pill, to see if it can shrink the cancer.
Hear when a new Treatment Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.